Genetic and therapeutic heterogeneity shape the baseline and longitudinal immune ecosystem of ovarian clear cell carcinoma.

J Immunother Cancer · 2024 · PMC11603735 · PMID 39608974

Europe PMC DOI

hedged sentences

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

borderline significantp=0.056so close (0.05 < p ≤ 0.1)

High POSTN expression alone showed a borderline significant correlation with unfavorable PFS (log-rank p=0.056).

also in 11,409 other papers

showed a trendno p-value reported

In phase II KEYNOTE-100 study, patients with OCCC showed a trend toward greater benefits from pembrolizumab (n=19, ORR=15.8%, 95% CI: 3.4% to 39.6%). 15 In phase III study of platinum-resistant OC, patients with OCCC experienced longer OS with nivolumab compared with chemotherapy (gemcitabine or pegylated liposomal doxorubicin) (HR: 0.78; 95% CI: 0.46 to 1.32).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.